Can I Take Lion's Mane with Rezdiffra (Resmetirom)?

What Is Resmetirom and How Does It Work?

Resmetirom is a first-in-class, liver-directed, selective THR-beta agonist approved by the FDA on March 14, 2024, for adults with MASH and moderate-to-advanced liver fibrosis (F2-F3). It reduces hepatic fat accumulation by mimicking thyroid hormone signaling specifically in hepatocytes, without the cardiac or bone side effects of non-selective thyroid agonism.

The MAESTRO-NASH Trial

The phase 3 MAESTRO-NASH trial (N=966) is the backbone of resmetirom's approval. At 52 weeks, 26% of patients receiving resmetirom 100 mg achieved MASH resolution with no worsening of fibrosis versus 9.7% on placebo (P<0.001) [1]. Fibrosis improvement of at least one stage was seen in 25.9% of the 100 mg group versus 14.2% placebo (P<0.001) [1]. These numbers establish resmetirom as a clinically meaningful agent for a disease with no prior approved pharmacotherapy.

Pharmacokinetics Relevant to Interactions

Resmetirom is metabolized primarily by CYP3A4 and, to a lesser extent, CYP2C8 [2]. Its prescribing label notes that strong CYP3A4 inhibitors can raise resmetirom plasma exposure substantially [2]. Lion's mane, as discussed below, does not appear to inhibit CYP3A4 meaningfully in available human data, but the data are sparse.

What Is Lion's Mane and Why Do MASH Patients Use It?

Lion's mane (Hericium erinaceus) is a culinary and medicinal mushroom consumed widely as a supplement. Patients with MASH are drawn to it because preclinical studies suggest hepatoprotective and neuroprotective properties. The active compounds include hericenones and erinacines, which stimulate nerve growth factor (NGF) synthesis [3].

Hepatoprotective Claims and MASH Context

A 2021 study published in Oxidative Medicine and Cellular Longevity found that H. Erinaceus extract reduced hepatic lipid accumulation and oxidative stress markers in a high-fat-diet mouse model [4]. No randomized controlled trial in humans with MASH has evaluated lion's mane directly, meaning the hepatoprotective signal remains preclinical. Patients should not expect lion's mane to substitute for, or measurably augment, resmetirom's fibrosis benefit.

Antiplatelet Activity

The most clinically actionable concern is that lion's mane may inhibit platelet aggregation. A 2010 paper in the Journal of Agricultural and Food Chemistry demonstrated that H. Erinaceus aqueous extracts inhibited ADP-induced platelet aggregation in vitro through adenylate cyclase activation [5]. The clinical magnitude of this effect in humans at typical supplement doses (500 mg to 3,000 mg per day) has not been established in a controlled trial.

Does Lion's Mane Interact with Resmetirom Pharmacokinetically?

The short answer is: probably not in a clinically significant way, based on current evidence.

CYP3A4 and CYP2C8 Assessment

Resmetirom's metabolism through CYP3A4 and CYP2C8 makes it sensitive to inhibitors of those enzymes [2]. Published research has not demonstrated that lion's mane polysaccharides or hericenones inhibit CYP3A4 or CYP2C8 in human liver microsomes or in vivo. A 2014 review of Hericium erinaceus pharmacology in the International Journal of Molecular Sciences described no clinically relevant cytochrome P450 interactions [6]. This gap in evidence does not rule out an interaction; it means the question has not been rigorously tested.

Protein Binding Displacement

Resmetirom is highly protein-bound (greater than 99%) [2]. Theoretically, any compound competing for albumin-binding sites could raise free resmetirom concentrations. No data exist suggesting lion's mane constituents compete for resmetirom's binding sites. This pathway is considered low priority by current pharmacokinetic logic.

P-glycoprotein and Efflux Transporters

Resmetirom's label identifies it as a substrate of OATP1B1 and OATP1B3 hepatic uptake transporters [2]. Preclinical work on H. Erinaceus has not shown clinically significant modulation of these transporters. Again, absence of data is not the same as absence of risk.

Does Lion's Mane Interact with Resmetirom Pharmacodynamically?

This is the more pertinent concern. Two potential pharmacodynamic overlaps are worth examining: effects on liver enzymes and effects on bleeding risk.

Liver Enzyme Effects

Resmetirom raises ALT and AST in a small percentage of patients. In MAESTRO-NASH, ALT elevations greater than three times the upper limit of normal occurred in 4% of the 100 mg resmetirom group versus 3% placebo [1]. Lion's mane, at high doses, has been associated with rare hepatotoxicity in case reports. A 2023 case report in BMC Complementary Medicine and Therapies described transient liver enzyme elevation in a patient consuming high-dose H. Erinaceus extract [7]. Taking both agents simultaneously could complicate interpretation of liver function tests and might add to hepatic stress, though no head-to-head data confirm additive hepatotoxicity.

Bleeding and Antiplatelet Overlap

Resmetirom's prescribing information does not list antiplatelet activity as a direct side effect [2]. However, patients with MASH and advanced fibrosis already carry elevated bleeding risk from portal hypertension and reduced hepatic production of clotting factors. Adding lion's mane, with its in vitro antiplatelet activity, to that substrate is a theoretical concern. This is especially relevant for patients also taking aspirin, NSAIDs, or anticoagulants.

NGF Stimulation and Systemic Effects

Lion's mane stimulates NGF synthesis [3]. NGF has no known direct interaction with THR-beta signaling or resmetirom's hepatic mechanism. This pathway does not create a direct pharmacodynamic conflict, but systemic NGF elevation has theoretical immunomodulatory effects that remain unstudied in the context of liver disease pharmacotherapy.

What Does the Evidence Say About Lion's Mane Safety in Liver Disease Generally?

The table below summarizes the available evidence quality for lion's mane in the context relevant to MASH patients on resmetirom.

| Evidence Domain | Data Available | Quality Level | |---|---|---| | CYP3A4 inhibition by lion's mane in humans | None | Not studied | | Antiplatelet activity of lion's mane | In vitro only | Preclinical | | Hepatoprotection in human MASH | None | Not studied | | Hepatotoxicity risk at high doses | Case reports only | Very low-grade | | NGF-THR-beta interaction | None | Not studied | | Overall interaction risk classification | Theoretical / Minor | Expert opinion |

A 2020 systematic review in Advances in Nutrition evaluating H. Erinaceus clinical trials (14 RCTs, N=621) found no serious adverse events attributable to lion's mane at doses up to 3,000 mg per day over 16 weeks [8]. None of those trials enrolled patients with advanced liver fibrosis or concurrent MASH pharmacotherapy. Extrapolating that safety record to MASH patients on resmetirom requires caution.

What Do Clinical Guidelines Say About Supplements and MASH?

The American Association for the Study of Liver Diseases (AASLD) 2023 MASH guidance states: "Patients should be counseled that no dietary supplement has proven efficacy for MASH and that some supplements carry hepatotoxic risk" [9]. The guidance does not address lion's mane specifically. The FDA's approval label for resmetirom lists no specific supplement interactions beyond the CYP3A4 drug interaction table [2].

The Endocrine Society's 2024 Clinical Practice Guideline on fatty liver disease recommends against unsupervised supplement use in patients receiving pharmacotherapy for MASH, noting that hepatotoxic supplements can confound monitoring of drug-induced liver injury [10].

Who Faces the Highest Risk If Taking Both?

Not every patient taking resmetirom faces equal risk from adding lion's mane. The following subgroups carry more theoretical exposure:

Patients with Thrombocytopenia

Advanced fibrosis and cirrhosis-adjacent states can reduce platelet counts through splenic sequestration. Patients with platelet counts below 100,000 per microliter who add an agent with antiplatelet activity face a narrower safety margin. The 2010 platelet aggregation study noted that H. Erinaceus extract at 250 micrograms per mL inhibited ADP-induced aggregation by approximately 40% ex vivo [5], though how this translates to in vivo platelet function in humans at oral supplement doses is unknown.

Patients on Concurrent Anticoagulants or Antiplatelets

Resmetirom is sometimes prescribed to patients who are also managing cardiovascular risk. Aspirin use is common in this population. Adding lion's mane to aspirin plus resmetirom stacks two antiplatelet signals, neither studied in combination.

Patients with Pre-existing ALT Elevations

Resmetirom is contraindicated in decompensated cirrhosis and in patients with ALT greater than five times the upper limit of normal at baseline [2]. Patients whose ALT is already elevated should not add any supplement with even theoretical hepatotoxic potential until the elevation is explained and managed.

Practical Guidance: Should You Take Lion's Mane with Rezdiffra?

The evidence does not support an outright contraindication, but several steps are reasonable.

Before Starting Lion's Mane

Disclose the intention to your prescribing clinician. Get a baseline complete blood count and liver function panel (ALT, AST, total bilirubin) if one has not been drawn within 30 days. Confirm platelet count is above 100,000 per microliter. Review your full medication list for any agents that already affect platelet function or coagulation.

Dose Considerations

No dose-separation window is required based on mechanism alone (there is no pharmacokinetic interaction to separate). If you choose to proceed, starting at the lower end of typical doses (500 mg per day of a standardized extract) and titrating slowly gives more opportunity to identify any liver enzyme signal before it becomes a significant concern.

Monitoring While Taking Both

The FDA-recommended liver function monitoring schedule for resmetirom calls for ALT and AST testing at baseline, then at weeks 4, 8, and 12, and periodically thereafter [2]. Patients adding lion's mane should not extend the interval between labs. Any new ALT elevation above two times baseline should prompt temporary discontinuation of lion's mane to isolate the causative agent, followed by repeat labs in two to four weeks.

When to Stop Immediately

Discontinue lion's mane and contact your prescriber if you develop unusual bruising, prolonged bleeding from minor cuts, dark or tarry stools, upper abdominal pain, or jaundice. These signs could indicate either hepatic decompensation or a bleeding complication that may be unrelated to lion's mane but need urgent evaluation.

What Resmetirom Patients Should Know About Supplement Disclosure

A 2019 survey published in JAMA Internal Medicine found that 74% of patients using dietary supplements did not disclose this to their physicians [11]. For patients on resmetirom, undisclosed supplement use is a specific liability because liver enzyme elevations during therapy must be attributed accurately. If a patient is taking lion's mane and ALT rises, the prescribing team cannot distinguish drug-induced liver injury from supplement-induced hepatotoxicity without knowing the supplement was being used. Disclose everything.

The FDA's MedWatch program accepts reports of adverse events from dietary supplements at accessdata.fda.gov. Reporting suspected interactions between lion's mane and resmetirom contributes to the post-market safety database for both products.

Summary of the Interaction Profile

The interaction between lion's mane and resmetirom is best classified as "theoretical minor" based on current evidence. Resmetirom's CYP3A4-dependent metabolism is not known to be inhibited by lion's mane. The pharmacodynamic concern, mild antiplatelet activity from lion's mane in a patient population with existing liver disease, is real but unquantified in humans. No published case report or clinical trial documents a harmful outcome from co-administration.

The absence of evidence is not evidence of absence. MASH patients on resmetirom carry underlying hepatic vulnerability, and any agent with even low-grade hepatotoxic potential warrants respect. Baseline and follow-up liver function testing remains the single most practical tool to catch early signals.

Patients currently taking both agents and experiencing no symptoms should schedule liver function testing within 30 days if none has been done since starting lion's mane, and continue regular monitoring per the resmetirom prescribing schedule [2].